Article information
Abstract
Abatacept is a new drug available for refractory rheumatoid arthritis (RA), as other biologic therapies this drug is not free of potentially serious adverse events. We present a case of a 73-year-old patient treated with abatacept who suffered a Legionella pneumophila type 1 pneumoniae.
Keywords:
Arthritis rheumatoid
Abatacept
Legionella pneumophila
Resumen
El abatacept es un nuevo fármaco disponible para el tratamiento de los pacientes con artritis reumatoide (AR) refractaria. No obstante, al igual que sucede con otros tratamientos biológicos, este tratamiento no está exento de potenciales efectos adversos. A continuación se presenta el caso de una paciente de 73 años, con AR tratada con abatacept, en el que se desarrolló neumonía por Legionella pneumophila tipo 1.
Palabras clave:
Artritis reumatoide
Abatacept
Legionella pneumophila
Full text is only aviable in PDF
References
[1]
P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
N Engl J Med, 343 (2000), pp. 1594-1602
[2]
M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Engl J Med, 340 (1999), pp. 253-259
[3]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[4]
R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group.
Lancet, 354 (1999), pp. 1932-1939
[5]
M.H. Buch, S.J. Bingham, D. Bryer, P. Emery.
Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders.
Rheumato- logy (Oxford), 46 (2007), pp. 1153-1156
[6]
S.B. Cohen, P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, et al.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum, 54 (2006), pp. 2793-2806
[7]
M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med, 353 (2005), pp. 1114-1123
[8]
M.C. Genovese, M. Schiff, M. Luggen, J.C. Becker, R. Aranda, J. Teng, et al.
Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Ann Rheum Dis, 67 (2008), pp. 547-554
[9]
K.L. Hyrich, A.J. Silman, K.D. Watson, D.P. Symmons.
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: An update on safety.
Ann Rheum Dis, 63 (2004), pp. 1538-1543
[10]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[11]
N.R. Slifman, S.K. Gershon, J.H. Lee, E.T. Edwards, M.M. Braun.
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alphaneutralizing agents.
Arthritis Rheum, 48 (2003), pp. 319-324
[12]
F.G. de Rosa, D. Shaz, A.C. Campagna, P.E. Dellaripa, U. Khettry, D.E. Craven.
Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: A possible healthcare-associated case?.
Infect Control Hosp Epidemiol, 24 (2003), pp. 477-482
[13]
T.L. Tai, K.P. O’Rourke, M. McWeeney, C.M. Burke, K. Sheehan, M. Barry.
Pneumocystis carinii pneumonia following a second infusion of infliximab.
Rheumatology (Oxford), 41 (2002), pp. 951-952
[14]
J.H. Lee, N.R. Slifman, S.K. Gershon, E.T. Edwards, W.D. Schwieterman, J.N. Siegel, et al.
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Arthritis Rheum, 46 (2002), pp. 2565-2570
[15]
L. Bergstrom, D.E. Yocum, N.M. Ampel, I. Villanueva, J. Lisse, O. Gluck, et al.
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.
Arthritis Rheum, 50 (2004), pp. 1959-1966
[16]
F. Tubach, P. Ravaud, D. Salmon-Ceron, N. Petitpain, O. Brocq, F. Grados, et al.
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.
Clin Infect Dis, 43 (2006), pp. e95-e100
Copyright © 2009. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
